David A. Roth
2014 - Infinity Pharmaceuticals
In 2014, David A. Roth earned a total compensation of $1.7M as Chief Medical Officer at Infinity Pharmaceuticals, a 67% increase compared to previous year.
Compensation breakdown
| Bonus | $250,000 |
|---|---|
| Non-Equity Incentive Plan | $160,000 |
| Option Awards | $893,650 |
| Salary | $397,102 |
| Other | $8,803 |
| Total | $1,709,555 |
Roth received $893.7K in option awards, accounting for 52% of the total pay in 2014.
Roth also received $250K in bonus, $160K in non-equity incentive plan, $397.1K in salary and $8.8K in other compensation.
Rankings
In 2014, David A. Roth's compensation ranked 5,195th out of 13,032 executives tracked by ExecPay. In other words, Roth earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,195 out of 13,032 | 60th |
Division Manufacturing | 1,854 out of 4,965 | 63rd |
Major group Chemicals And Allied Products | 617 out of 1,690 | 64th |
Industry group Drugs | 469 out of 1,369 | 66th |
Industry Pharmaceutical Preparations | 373 out of 1,042 | 64th |
Source: SEC filing on April 25, 2016.
Roth's colleagues
We found four more compensation records of executives who worked with David A. Roth at Infinity Pharmaceuticals in 2014.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019